GPLD1 and glioblastoma: The demonstrated efficacy in different GBL cell lines that exhibit different phenotypical features and different degrees of TMZ sensitivity suggest that the use of CUR+PLD as an integrated therapy might be beneficial in poorly differentiated and multifaceted tumors such as glioblastoma multiforme.